San-Miguel, J. F., Hungria, V. T. M., Yoon, S., Beksac, M., Dimopoulos, M. A., Elghandour, A., . . . Richardson, P. G. (2014). Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial. The lancet oncology, 15(11), 1195-1206. https://doi.org/10.1016/S1470-2045(14)70440-1
Citace podle Chicago (17th ed.)San-Miguel, Jesús F., et al. "Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: A Multicentre, Randomised, Double-blind Phase 3 Trial." The Lancet Oncology 15, no. 11 (2014): 1195-1206. https://doi.org/10.1016/S1470-2045(14)70440-1.
Citace podle MLA (9th ed.)San-Miguel, Jesús F., et al. "Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: A Multicentre, Randomised, Double-blind Phase 3 Trial." The Lancet Oncology, vol. 15, no. 11, 2014, pp. 1195-1206, https://doi.org/10.1016/S1470-2045(14)70440-1.